Triple Negative Breast Cancer: Immunotherapies and Biomarkers

IMPACT Medicom

English - March 21, 2022 15:00 - 16 minutes - 11 MB
Science impact medicom medical communications medical writing agency Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Prophylaxis de la COVID-19: Protection des patients immunodéprimés - Ep5 - Introduction (Francais)

Next Episode: Immunotherapy in HNSCC Series: Ep 1 - PD-L1 testing

In this episode, we discuss the treatment of triple negative breast cancer (TNBC) with Dr. Stephen Chia. We cover:

The use of immunotherapies to treat TNBCBiomarkers that can determine which patients will best respond to immunotherapiesThe challenges of testing for PDL-1

Our Guest:
Dr. Stephen Chia is a professor in the division of medical oncology and staff medical oncologist with BC Cancer, in Vancouver. He has held many leadership roles at BC Cancer, including Head of the Division of Medical Oncology UBC, Head of the Department of Clinical Research, BC Cancer, and Chair of the BC Cancer Breast Tumour Group. He has also been the Co-Chair of the Breast Disease Site for Canadian Cancer Trials Group (CCTG).

This podcast episode was sponsored by Merck Canada.

If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com